Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have stage IV prostate cancer that has not responded to hormone therapy.

Key facts

Study ID

NCT00004149

Run by

Albert Einstein College of Medicine

People needed

37

Starts

1999-09-01

Expected to finish

2003-08-01

Last updated by the study team

2018-08-17

Who can join

Age: any, up to 120. Sex: male. Healthy volunteers: not accepted.

You may not qualify if…

• No significant active infectious disease
• No grade 2 or greater peripheral neuropathy
• No other debilitating acute or chronic co-morbid medical, neurological, or psychiatric condition that would preclude study compliance
• No concurrent amphotericin B or other agent that prevents restoration of potassium or magnesium to normal levels and/or correction of QT interval to under 500 milliseconds

Where it is running

• Mount Sinai Medical Center, NY — New York, New York, United States
• Jacobi Medical Center — The Bronx, New York, United States
• Albert Einstein Clinical Cancer Center — The Bronx, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.